Get the Stockscreener App
7.33
10.39%
0.69
After Hours:
7.15
-0.18
-2.46%
Longeveron Inc stock is traded at $7.33, with a volume of 66,709.
It is up +10.39% in the last 24 hours and up +959.10% over the past month.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
See More
Previous Close:
$6.64
Open:
$6.79
24h Volume:
66,709
Relative Volume:
0.20
Market Cap:
$23.37M
Revenue:
$1.22M
Net Income/Loss:
$-22.43M
P/E Ratio:
-6.3386
EPS:
-1.1564
Net Cash Flow:
$-18.78M
1W Performance:
+7.64%
1M Performance:
+959.10%
6M Performance:
+802.15%
1Y Performance:
+822.01%
1-Day Range:
$6.64
$7.3597
1-Week Range:
$6.50
$7.3597
52-Week Range:
$0.475
$7.3597
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
7.33 | 23.37M | 1.22M | -22.43M | -18.78M | -1.1564 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
192,308 Longeveron (NASDAQ: LGVN) shares sit with one passive fund - stocktitan.net
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
Longeveron Stock Price Forecast. Should You Buy LGVN? - StockInvest.us
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming DeadlineLGVN - TMX Newsfile
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
A biotech presentation is set for New York on Sept. 14 - stocktitan.net
Longeveron | 4: Statement of changes in beneficial ownership of securities - Moomoo
Longeveron (LGVN) Gains 2.68% as Shares Hold Above Key Support at $6.55Breakout Confirmation - vinanet.vn
Longeveron To Carry Out 1-for-10 Reverse Stock Split On August 27th, 2026 - Moomoo
Longeveron Announces 1-for-10 Reverse Stock Split to Regain Nasdaq Compliance - intellectia.ai
Dick's Sporting Goods, Intuit And 3 Stocks To Watch Heading Into Tuesday - Sahm
Longeveron Announces 1-for-10 Reverse Stock Split - The National Law Review
Longeveron Announces 1-For-10 Reverse Stock Split - TradingView
Longeveron Inc. Earnings Call: Trials, Cash and Risk - TipRanks
Longeveron (NASDAQ: LGVN) insider logs new stock trades - Stock Titan
Longeveron (LGVN) grants director 36,000 stock units - Stock Titan
Longeveron (NASDAQ: LGVN) insider reports new stock dealings - Stock Titan
Longeveron (NASDAQ: LGVN) insider reports stock trades - stocktitan.net
Longeveron (LGVN) Q2 2026 Earnings Call Transcript - AOL.ca
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer - manilatimes.net
Longeveron (LGVN) Earnings Reading: Profit Per Share Falls Below Its Benchmark at the Close; After Results: The Stock Gains 4.46% in the Current UpdateProfitability Analysis - vinanet.vn
Longeveron appoints Nirav Jhaveri as chief financial officer - Investing.com Nigeria
Longeveron Appoints Nirav Jhaveri as CFO Ahead of September Trial Data - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed - TipRanks
Longeveron Appoints New Chief Financial Officer Jhaveri - TipRanks
Longeveron Appoints Nirav Jhaveri As CFO - marketscreener.com
Longeveron appoints Nirav Jhaveri as chief financial officer By Investing.com - Investing.com India
Longeveron Inc. Appoints Nirav Jhaveri as Chief Financial Officer - Quiver Quantitative
September Stem Cell Trial Results Expected as Longeveron Names CFO - stocktitan.net
Marie Washburn Net Worth (2026) - GuruFocus
Longeveron reports Q2 EPS (19c) vs. (33c) last year - TipRanks
$Longeveron (LGVN.US)$ - Moomoo
Longeveron Inc. (LGVN) investors disclose 9% beneficial stake through warrant holdings - Stock Titan
Longeveron LLC earnings missed by $0.01, revenue fell short of estimates - Investing.com Nigeria
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update - BioSpace
Longeveron Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Longeveron Q2 EPS $(0.19) Misses Estimate, Sales Fall 9% - scanx.trade
LGVN: Q2 2026 net loss rose to $6.1M as HLHS trial data and XPRIZE finalist status drive near-term focus - TradingView
Earnings call transcript: Longeveron misses Q2 2026 estimates as cash runs tight - Investing.com
Longeveron Inc. (LGVN) Q2 FY2026 earnings call transcript - Yahoo Finance
Longeveron Reports $6.1 Million Q2 Net Loss Ahead Of ELPIS II Data - Quiver Quantitative
Longeveron Q2 net loss widens on higher legal, clinical trial costs - TradingView
LGVN: Q2 2026 net loss rose 22% as clinical and legal expenses increased ahead of key trial results - TradingView
BRIEF-Longeveron Q2 EPS USD -0.19 - TradingView
Longeveron Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Longeveron (LGVN) Rises 7.92% to $0.75, Approaches Key Resistance at $0.79Retracement Entry - vinanet.vn
Earnings To Watch: Longeveron Inc (LGVN) Q2 2026 -- GF Value Sees 58% Downside - Yahoo Finance
Longeveron Selected as XPRIZE Healthspan Milestone 2 Awardee for Laromestrocel Clinical Trial Results - Quiver Quantitative
Longeveron Named a Finalist Team and Will Receive a - GlobeNewswire
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):